Cardiothoracic & vascular anesthesia
Vasopressin and Major Adverse Kidney Events in Patients Requiring Vasopressor Support After Cardiac Surgery: A Multicenter Retrospective Cohort Study
Main findingResult — go to the resultOdds ratio 1.02 95% CI 0.76–1.38Authors' conclusion
Adjunctive vasopressin use was not associated with major adverse kidney events or mortality in patients requiring vasopressors after cardiac surgery.
Study context
- Population
- Adults requiring ≥6 consecutive hours of vasopressor support within the first 24 h after cardiac surgery (CABG, valve or combined), 4 ICUs in Queensland, Australia, 2015–2021; ECMO excluded
- Participants
- 3,753 adults
- Exposure
- Vasopressin within 24 h of ICU admission vs no vasopressin
- Vasopressinn = 603
- Outcome
- Major adverse kidney events:
- Death
- New RRT
- Creatinine doubling
- Follow-up
- 30 days
Methodological detailsmulticentre, inverse probability of treatment weighting with overlap weights
- Multicentre
- Inverse probability of treatment weighting with overlap weights
Main finding
As reported in the abstract
Odds ratio
1.02
95% CI 0.76–1.38
P = 0.88
Vasopressin vs No vasopressin
OR 1.02 (95% CI 0.76–1.38); P = 0.88
Observational data: associations, not effects.
Further findings
MAKE at 30 days by illness severity (subgroup)
- Significant interaction for illness severity, with a trend toward benefit of vasopressin in the highest-severity tertile
- Interaction p = 0.004
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Vasopressin and Major Adverse Kidney Events in Patients Requiring Vasopressor Support After Cardiac Surgery: A Multicenter Retrospective Cohort Study. J Cardiothorac Vasc Anesth. Published 8 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →